 |
|
|
| |
High SVR Rates in Patients With Genotype 4 Chronic Hepatitis C Infection and Compensated Cirrhosis Treated With Ombitasvir/Paritaprevir/Ritonavir Co-Administered With Ribavirin (AGATE-I)
|
| |
| |
Reported by Jules Levin
April 14-17 Barcelona
Tarik Asselah1, Christophe Hezode2, Roula B Qaqish3, Magdy ElKhashab4, Tarek Hassanein5, George Papatheodoridis6, Jordan J Feld7, Saleh Alqahtani8, Antonio Olveira Martí n9, Tami Pilot-Mati as3, Yao Yu3, Rebecca Redman3, Niloufar Mobashery3
1Centre de Recherche sur l'Inflammati on, Inserm UMR 1149, Universite Paris Diderot, AP-HP Hôpital Beaujon, Clichy, France; 2Hôpital Henri Mondor, AP-HP, Universite Paris-Est, Creteil, France; 3AbbVie Inc., North Chicago, Illinois, United States; 4Toronto Liver Centre, Toronto, Ontario, Canada; 5Southern California Liver Centers and Southern California Research Center, Coronado, California, United States; 6Department of Gastroenterology, Medical School of National and Kapodistrian University of Athens, Laiko General Hospital, Athens, Greece; 7Toronto Centre for Liver Disease, University of Toronto, Toronto, Ontario, Canada; 8The Johns Hopkins Hospital, Baltimore, Maryland, United States; 9Department of Gastroenterology, Hospital Universitario La Paz, Madrid, Spain
|
| |
|
|
|
|
|
